Results 161 to 170 of about 2,131 (185)

Efficacy and safety of fremanezumab for chronic migraine prevention: Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients

Headache, 2021
Nobuyuki Koga, Fumihiko Sakai, Norihiro Suzuki   +2 more
exaly  

Efficacy and safety of fremanezumab for episodic migraine prevention: Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients

Headache, 2021
Nobuyuki Koga, Fumihiko Sakai, Norihiro Suzuki   +2 more
exaly  

Erenumab/fremanezumab/galcanezumab

Reactions Weekly, 2023
openaire   +1 more source

Fremanezumab zugelassen

NeuroTransmitter, 2019
openaire   +2 more sources

Efficacy and safety of fremanezumab for migraine prophylaxis in patients with at least three previous preventive failures: Prospective, multicenter, real-world data from a Greek registry

European Journal of Neurology, 2023
Georgia Xiromerisiou, Michail Vikelis, Andreas A Argyriou   +2 more
exaly  

Dose selection for fremanezumab (AJOVY) phase 3 pediatric migraine studies using pharmacokinetic data from a pediatric phase 1 study and a population pharmacokinetic modeling and simulation approach

Cephalalgia, 2021
Jill Fiedler-Kelly, Yoel Kessler, Xiaoping Ning   +2 more
exaly  

Monthly versus quarterly fremanezumab for the prevention of migraine: a systemic review and meta-analysis from randomized controlled trials

Naunyn-Schmiedeberg's Archives of Pharmacology, 2020
Zhouqing Chen, Zhong Wang, Zhong Wang
exaly  

Erenumab/Fremanezumab

Reactions Weekly
openaire   +2 more sources

Fremanezumab as Add-On Treatment for Patients Treated With Other Migraine Preventive Medicines

Headache, 2017
David W Dodick, Ernesto Aycardi, Joshua M Cohen   +2 more
exaly  

Population pharmacokinetic modelling and simulation of fremanezumab in healthy subjects and patients with migraine

British Journal of Clinical Pharmacology, 2019
Michele Rasamoelisolo, Micha Levi, Orit Cohen-Barak   +2 more
exaly